ImmuCell posted GAAP net income of $1.8 million for Q2 2026, up from $502,000 a year earlier; diluted EPS was $0.20.
Revenue rose 11.5% to $7.2 million, while gross margin fell 9.8 percentage points to 33.9%.
Results included a one-time $2 million legal settlement from a former Re-Tain contract manufacturer, booked as lower operating expenses.
Non-GAAP adjusted EBITDA increased to $2.7 million from $1.4 million in the prior-year quarter.
The board authorized a two-phase First Defense capacity expansion: about $3.5 million for freeze-drying, then about $4.5 million for liquid processing.
ICCC•
